click company/industri name report summari
price estim chang
miss fairway good lie first cut maintain buy pt
result guid good enough buy pt
solid advertis tool bring upsid buy pt
lower guidanc on-going tariff impact us sale maintain hold price target
updat outlook improv near-term optic issu keep us sidelin pt
long durat opportun still top larg cap pick buy modest dip rais price target
solid partnership delay impact guidanc hold pt
make progress multipl front despit ep shortfal self-sustain growth key
take-away buy pt
braini approach develop roll ahead reiter buy pt
fda action allergan implant leav open maintain buy price target
diagnost tool
quick take ghdx freenom seri
summari publish mon-fri includ report publish sinc recent edit pleas refer individu report specif public price date
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect invest analyst person independ object view
design invest relev issuer discuss herein
research report uk produc canaccord genuiti limit authoris regul financi conduct author fca report
european issuer non-independ research market commun market abus regul fca conduct busi rule
canaccord genuiti australia limit australian affili global capit market group canaccord genuiti group inc cf tsx recommend
opinion express research report accur reflect analyst person independ object view design invest
import inform pleas see import disclosur begin page document
back index
aerospac defens
ba report core ep compar estim
use quarter revenu
result unexpect charg pre-announc last week
howev investor react neg increment caution
return servic rt time potenti increment financi headwind
result ground continu believ ground recoveri
justifi caution time standpoint maintain hold rate
clearli still time risk around rt ba
manag struck cautiou tone view believ fact
manag highlight potenti temporari shutdown line
ground move right spook investor believ risk
downsid chang differ tone manag
noteworthi ba manag also gone way highlight time
realli regulatori driven alway case believ best case
ba phase approach north american regul lift ground
follow european chines regul believ cost
assumpt ba roughli reflect time
step-up signific believ long-term
upsid ba reset lower level rel prior estim much
identifi cost associ custom concess front end load
ba recov deliveri assum ba slight share
buy-back acceler revis estim call
howev believ increment upsid
limit price delay potenti acceler nma
relat develop cost post ramp import factor
sentiment stock view
also indic first flight slip earli due
challeng engin believ entri servic ei realist
updat backlog expect dubai airshow later
ba indic expect maintain product rate
evalu rate ba see strong demand
enabl compani maintain least rate backlog
still expect peak year develop spend cash
acceler program expect deliveri expect start
get push
maintain hold rate price target believ
still signific risk associ rt headlin risk ba navig
re-certif process post-max face risk time potenti nma
price pressur moreov sentiment health commerci cycl
weaken traffic growth slow order activ
mute believ order activ import factor broader sector
sentiment
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
miss fairway good lie first cut maintain
bottom line bsx print bmo wed essenti line expect
henc ho-hum respons stock today importantli commensur
thesi come note recent analyst day note
think setup stock attract go back half
surmis firm pois deliv acceler revenu growth
expand oper margin strong double-digit ep growth estim
drive stock least target next month
henc stay buy-rat would pick spot name market pullback add
manag organ top-lin growth guidanc maintain
impli sale acceler first half growth think probabl
firm achiev least mid-point note prolif pipelin catalyst recent
product launch first reason confid name watchman flx europ
watchman market launch japan acur ramp europ lotu edg launch
us/eu sentinel suppli issu eas ramp contribut uroph new portfolio
addit augmenix turn organ octob nxthera turn may
augment via recent acquisit vertiflex btg pend deal closur
august what also optimist new product launch on-going
invest ep busi think acceler well
mention potenti continu execut smart tuck-in acquisit
manag intim could pick volum perspect
leverag increasingli unencumb balanc sheet
outlook reiter manag continu anticip total sale growth
rang report basi includ approxim
impact recent acquisit nxthera claret augmenix vertiflex btg
contribut current includ guidanc manag provid updat
guidanc follow deal closur current anticip august adjust ep
continu expect rang
guidanc manag anticip total report sale growth
rang organ revenu growth expect rang
exclud approxim expect contribut recent acquisit
claret augmenix vertiflex current rate fx expect
headwind adjust ep anticip rang y/i
bullish structur heart guidanc re-affirmed firm today reiter
sale outlook structur heart busi anticip total sale rang
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
result guid good enough buy pt
reiter buy recommend believ share work higher
execut oper transform share repurchas program newli initi
dividend compani highlight uniqu opportun focus improv
streamlin busi drive improv profit effort take hold
share respond favor
posit book beat estimate con
approach top-end guidanc management note nearli exceed
target despit walk away busi meet compani new
neg margin expect flat sequenti thu lead adj-ep
guidanc estim consensu
result mostli posit book adj-ep beat revenue miss
con slightli although came in-lin estimate book y/
beat cg con came high-end guidanc
revenu y/i in-lin cg
slightli miss con near mid-point guidanc
encourag licens revenu outpac expect howev
off-set lower anticip low-margin tech resal adj-ep
y/i beat cg con guidanc note
compani report tax rate non-
forecast
guidanc establish book revenue
bracket previou cg con estim adj-ep guidanc
con previou estimate high-end
previou margin target re-affirmed howev expect flat
thu adj-ep move lower manag indic detail list
opportun part oper transform initi re-affirmed adj-
om target compani reiter
benefit would back-end load thu guid adj-om rel flat
adj-ep guidanc lower
estimate annual estim remain given
beat
three key area highlight point focu growth come
year first desir becom saa platform healthcar
expect total transit millennium base newer growth area like
saas-bas second compani continu target growth channel outsid
tradit hospit environ third seek monet signific data
presenc organ biopharma insur
valuat rais pt base adj-
ep estim in-lin cern averag
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
solid advertis tool bring upsid buy pt
facebook report solid result stabl user trend acceler advertis
revenu growth led upsid consensu stronger ad revenu
mainli heel sever ad product updat slower anticip
impact privaci chang manag continu expect revenu deceler
next year ad-target relat headwind like kick-in
consensu alreadi price slower revenu growth think improv stori
monet on-going strong execut could lead upsid estim
rais price target
stori continu drive engag facebook mau dau grew
leav engag daus/mau roughli unchang asia row
remain main driver dau expans respect india
indonesia philippin continu lead dau growth matur market
us canada europ remain stori continu drive engag
across facebook entir famili app dau reach
mau
advertis growth acceler new tool benefit smb advertis revenu
increas y/i ex-fx vs facebook
introduc new ad tool aim help smb includ new video edit tool
quickli creat eye catch video advertis exist imag autom
ad advertis complet brief survey receiv custom market
plan six creativ option target suggest recommend
budget facebook also enhanc exist ad product feed ad
refresh user scroll lead relev ad placement
improv roi advertis dynam ad instagram stori roll ad
within instagram explor tab also introduc quarter
ftc settlement offici prior releas earn facebook announc
compani reach settlement agreement ftc follow
month probe cambridg analytica breach includ financi
penalti new framework oversight part agreement compani
agre quarterli certif verifi privaci control work
includ sign-off ceo mark zuckerberg facebook also confirm ftc
open anti-trust investig compani june addit
recent announc anti-trust review market-lead on-line platform doj
guidanc impli delay impact privaci headwind guidanc continu
call deceler revenu growth pronounc impact
total expens growth ex-ftc accrual expect
unchang last quarter capital-expenditure adjust
primarili alloc spend data center server
estim chang valuat modestli rais estim increas
pt base adj ebitda estim also
support dcf valuat
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
lower guidanc on-going tariff impact us sale
maintain hold price target
report soft revenu vs estim
street ep estim street
revenu guidanc lower versu
forecast street estim ep guidanc lower
versu estim street
confer call compani state primari driver lower
guidanc increas tariff may
note compani indic impact felt broadli across us
product offer price increas affect elast demand
one bright spot amazon prime day event year includ three
offer compani highest-pr roomba sell first
primari concern come guidanc rang impli strong
ramp depend upon solid perform new roomba
braava product signific shortfal embed new guidanc rang
attribut tariff appear investor continu cautiou either
tariff issu resolv consum traction new product clear
maintain hold rate set new price target base
upon new ep estim
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
updat outlook improv near-term optic
issu keep us sidelin pt
bottom line report slightli lower-than-expect organ growth
albeit strength recent acquir product drove report growth
small top-lin beat compani deserv credit deliv upsid
albeit aid rel conserv guidanc rais today
y/i organ growth previous out-performance firm
two recent acquisit line see leverag opex near
term howev compress gm line hinder om leverag
estim potenti improv whenc see increment driver
om growth rais op-incom growth target
previous model continu look like show modest de-lever
cours year
posit note growth allograft solid suppli chain issu
larg work product pull cross sell opportun
recent acquir product support organ growth quarter
compani histor lever growth asp increas contribut much late
think new product launch xenosur durasur could provid
asp gm uplift stave share loss compani expand biolog portfolio
sale vs look forward question compani
acquisit histor lmat mo valuat
med-tech all-tim high given tradit valu buyer
current zeitgeist may bit firm comfort zone said believ
firm cash flow balanc sheet consumm tuck-in think
may necessari expand oi materi wit continu believ organ
oi expans remain harbing share appreci go forward
put take organ vs acquir growth play dont
believ enough us construct stock reiter
hold rate albeit nudg price target owe larg part higher comp
growth driver deliv organ y/i growth quarter recent
acquir product appli medic cardial deliv growth
expect busi annual run rate combin
began pull addit organ growth legaci embolectomi
cathet polyest graft sale allograft graft grew y/i suppli
chain issu hinder growth larg work
point sale america ou market bolster
compani new singapor offic lead top-lin growth emea
apac albeit slow growth respect
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
buy modest dip rais price target
share fade bit post print surpris quarter ever
slightli pristin inde probabl half question call circl around
get manag help caller build model obvious firm risk
lose foot especi compani yet achiev sustain scale model
question matter howev reach scale competit set compris
almost exclus legaci sub-scal firm segment softwar liter
account half softwar use realli struggl get agit
fundament inde past predestin everi time
share dip sinc ipo buy opportun noth
cheap softwar day believ remain best-in-class firm
mani year come well take ah pullback opportun get bit
sale price buy
differ view biggest surpris now report subscript
revenu mid-point guidanc year sinc report quarter
beat oftentim meaning high end guidanc currency-adjust
growth deceler point sequenti challeng y-o-i
comparison said forward-look metric name rpo subscript
bill solid view grow adjust basi respect
addit wed note larg deal activ continu transact acv
quarter year ago firm custom
acv y-o-i
bullish item larg deal sever data point end
custom acv firm top deal includ
product firm sign one largest new custom deal ever financi
institut purchas portfolio product firm forthcom new
york releas includ new mobil mobil onboard capabl
import addit partnership quarter announc partnership
azur beyond go-to-market synergi give help secur
clearanc better pursu feder opportun
bearish item time subscript revenu neg impact
renew shift largest self-host feder contract
impact move up-front revenu guidanc
reiter rais full year outlook across everi line item wed note
increas revenu unchang margin less accustom
see firm valuat share trade ev/r ev/
come print stock price anoth strong upsid
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
paypal report solid result essenti in-lin guidanc
consensu continu see paypal offer solid growth prospect limit
oper leverag past year consensu non-gaap ep estim
paypal increas stock
multipl expans seem driven stock market strength along
financials-ori investor look stock attract growth altern
financi stock would surpris see multipl expans continu
suspect stock need see upward estim revis work go forward
lead y/i growth fourth quarter row tpv grew y/i fx-neutral
show slight uptick three prior quarter fx-neutral growth help
merchant servic tpv growth mobil tpv growth mobil
tpv revenu grew y/i slight deceler gener
top paypal volum funnel perform well
partnership price delay impact guidanc far-reach collabor
mercadolibr paymentu delay push revenu lead
revis revenu growth guidanc manag
comment scope partnership particularli mercadolibr
expand lead larger long-term opportun delay start
revenu addit paypal delay plan price increas certain
servic pend product improv
venmo remain major bright spot venmo tpv grew deceler slightli
growth billion track deliv tpv
venmo user engag
monetiz transact exist signific headroom improv monet
marqui merchant like seamless hulu fandango addit
venmo ad number new merchant partner includ fandango stitch
venmo revenu still somewhat immateri less
overal paypal stay trajectori becom meaning next
mix guidanc revenu guidanc billion
broadli line prior estim roughli consensu non-gaap
ep guidanc also exactli line prior estim howev
manag lower revenu outlook around midpoint
call growth rais ep rang
account benefit meli
invest dilut recent acquisit
make minor estim chang increas price target
base unchang non-gaap ep estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
make progress multipl front despit ep
shortfal self-sustain growth key take-away buy
pt
post result roughli expect bear focu
wider loss feel result suggest bit time grow
specif quarter compani report revenu ep
comparison expect
critic compani end quarter cash gener
free cash flow quarter manag comment cash level
expect rise subsequ quarter year
compani maintain deliveri guidanc
total vehicl product expect ramp current per week run rate
end year
casual announc retir jb straubel co-found mark
yet anoth high profil execut exit concern level turnov
continu exist like speak cultur key variabl disrupt
sector
shanghai gigafactori progress track product
schedul view compani maintain lead ev revolut
present canaccord genuiti futur transport event august
boston contact cg repres detail
maintain buy rate set pt base upon appli
multipl new ep estim
back index
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
braini approach develop roll
clariti plan mdd phase data remain crucial
earlier today host d/portfolio review showcas
breadth central nervou system-focus pipelin expect report
open-label data bipolar depress show promis
interest phase data essenti cognit
dysfunct investor perspect biggest updat plan
pursu treatment-resist depress trd oral prior bipolar
depress gener anxieti disord larg market us patient
understand somewhat tepid stock reaction today event continu
like stock base two key factor import catalyst come
form phase data mdd recal work well
phase mdd phase smartli diversifi portfolio becom
signific player space medium long-term last point
remind investor present special challeng therapeut develop
make area somewhat insul term competit pressur smart
risk-tak gener significantli high reward target market
larg dcf-base pt unchang reiter buy
trd rel tough indic decis appear well thought us
believ decis pursu trd ahead bipolar depress make strateg
sens unmet need trd remain high leverag compon
major depress disord mdd postpartum depress program
preserve/enh abil bring oral market rel quickli
move might help spur usag mdd success developed/
approv make payor discuss somewhat easier trd model
bipolar depress probabl approv launch
quick look trd post-hoc bipolar depress open label data
trd post-hoc analysi done anti-depressant-unrespons patient
pivot ppd/mdd studi show appear work set
comparison data head-to-head vs product approv trd pleas
see tabl caveat data open label like earli promis shown
bipolar depress head-to-head data exist either
respons treatment period stretch seem compar
approv product week label data see tabl madr score comparison
intrigu data essenti tremor cognit dysfunct
tremor reduct singl dose back earlier work done
brexanolon show robust improv execut
function healthi volunt expect provid updat
time phase studi plan neurodegen
disord huntington parkinson alzheim exampl
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
biomed devic servic
fda action allergan implant leav open
happen morn allergan announc voluntari world-wide recal
biocel silicon saline-fil textur breast implant tissu expand
effect immedi compani stop sell implant market
current avail recommend provid return
unus product back compani remind come heel
regulatori action taken europ earlier year fda panel late march
regard emerg breast implant-associ anaplast larg cell lymphoma
bia-alcl see previou note fda
initi releas statement may stop short materi product
regulatori chang admit opportun regul
commit collect data follow month fda collect
data addit bia-alcl case bring new world-wide report total
attribut allergan implant furthermor death
occur patient bia-alcl implant manufactur known
attribut allergan base inform fda conclud allergan
biocel implant risk textur implant manufactur
continu distribut would like caus seriou health consequ result
fda request allergan recal specif model textur breast implant
us market
impact opportun announc surpris given
on-going trend breast implant market previou product ban and/or
recommend ban intern market includ franc led
recal across eu ce mark market uk canada australia singapor howev
continu think heighten focu implant safeti opportun
particularli come brand physician mind-shar perspect
recal major impact us market use textur
implant significantli lower estim smooth us vs
smooth ou import note us physician live/practic bubbl
regulatori clinic concern ou peer open opportun
manufactur affect recal -- name furthermor despit
numer headwind surround breast implant abl
add new account place singl order previou year someth
view posit evid potenti take share second half
despit broader headwind major player like allergan bottom line
remov financ overhang june link improv inventori backdrop
continu expect refin commerci strategi focu immedi
share-tak opportun present recal major product line ww
market leader posit compani drive sustain capital/recur revenu
beyond share ytd sinc summer
current trade ev/sal would surpris
aggress investor start build posit look detail
call august
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
back index
diagnost tool
price close busi juli
diagnost tool
quick take ghdx freenom seri
busi morn offer quick thought three develop
morn chairman ceo jon ayer medic leav
sinc june seriou bicycl injuri commun via sustain
sever spinal-cord injuri spoke confirm jon good spirit
suffer head brain injuri expect full-tim rehab take month
plan return soon howev unfortun current
mobil leg finger torso updat welcom news given prior
concern brain injuri believ mr ayer competit person
ever met believ fight return thought go jon
work hard stage spectacular recoveri meanwhil confid
exist team mention posit recent board addit ad
cfo applaud appoint board given tenur
except juggernaut large-growth compani experi intern
commerci financi acumen think cost sequenc keep
drop may look incorpor sequenc offer
ghdx encourag see ghdx today ad
small-cap effect juli believ news help turn around
stock slump late fundament reason believ
turnov sharehold base key reason continu like ghdx
fundament strong even today move trade street
rev feb peak larger group averag ghdx
hold uniqu qualiti industri leader breast prostat cancer test
elit strong manag rise profit reason valuat
freenom privately-held freenom today announc close seri
round bring all-in financ date led ra capit manag
gv andreessen horowitz section verili life scienc other seri
round appear second largest sector histori second grail
seri one adjust inflat multipl re-rat
bull market larg seri foundat medicin
nanostr
note thrive rais seri eight
week ago freenom plan conduct pivot valid studi dual submiss
fda parallel review program colon cancer screen
freenom lock assay look combin cell-fre dna methyl
protein achiev high level sensit specif continu like exact
scienc believ take year freenom well gh thrive grail
get market view liquid biopsi threat due biolog
technolog reason time get uspstf guidelin expect
difficulti get medicar coverag difficulti achiev high level sensit
stage cancer detect stage stage
patient prospect trial other achiev
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
